Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.

NHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell therapy for certain types of lymphoma, after the company’s specialist Kite unit struck a ...

Stay up-to-date on Kite Realty Group Trust Common Stock (KRG) Dividends, Current Yield, Historical Dividend Performance, and Payment Schedule.